Share This

Khosrow Kashfi

Faculty and Staff Profiles

Khosrow Kashfi

Associate Medical Professor
Chemistry Program Director

Harris Hall 201
Phone Number: 

Dr. Kashfi is also the Medical and Physician Assistant Pharmacology Course Director.


Ph.D., 1992, University of Tennessee

M.Sc., 1976, Cranfield Institute of Technology

B.S., 1974, Kingston Polytechnic

Courses Taught

MED 10200 - Principles of General Chemistry - Course Director

MED 20300 - Bio-Organic Chemistry - Course Director

Research Interests

Biology of colon and pancreatic cancers and their chemo prevention

Regulation of lipid metabolism including eicosanoids. 


Chattopadhyay M, Kodela R, Olson KR, and Kashfi K. (2012) NOSH-aspirin (NBS 1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model. Biochem. Biophys. Res. Comm. (in press)      
Kodela R, Chattopadhyay M, and Kashfi K. (2012) NOSH-aspirin: A novel nitric oxide- hydrogen sulfide-releasing hybrid: A new class of anti-inflammatory pharmaceuticals. ACS Med. Chem. Lett. (in press)      
Chattopadhyay M, Kodela R, Nath N, Street CA, Velázquez CA, Boring D, and Kashfi K. (2012) Hydrogen sulfide-releasing aspirin modulates xenobiotic metabolizing enzymes in vitro and in vivo. Biochem Pharmacol. 83, 733-740.      
Chattopadhyay M, Kodela R, Nath N, Barsegian A, Boring D, and Kashfi K. (2012) Hydrogen sulfide-releasing aspirin suppresses NF-B signaling in estrogen receptor negative breast cancer cells in vitro and in vivo. Biochem Pharmacol. 83, 723-732.      
Chattopadhyay M, Kodela R, Nath N, Dastagirzada YM, Velázquez CA, Boring D, and Kashfi K. (2012) Hydrogen sulfide-releasing NSAIDs inhibit the growth of cultured human cancer cells: A general property and evidence of a tissue type-independent effect. Biochem Pharmacol. 83, 715-722.      
Jain S, El Gendy MAM, Kashfi K, Jurasz P, and Velázquez CA. (2012) Nitric oxide release is not required to decrease the ulcerogenic profile of NSAIDs. J. Med. Chem. 55, 688-696.      
Kodela R, Chattopadhyay M, Nath N, Cieciura LZ, Pospishill L, Boring D, Crowell JA, and Kashfi K. (2011) Synthesis and biological activity of acetyl-protected hydroxybenzyl diethyl phosphates (EHBP) as potential chemotherapeutic agents. Bioorg. Med. Chem. Lett. 21, 7146-7150.      
Kashfi K, Mynatt RL, Park EA, Cook GA. (2011) Membrane Microenvironment Regulation of Carnitine Palmitoyltranferases I and II. Biochem. Soc. Trans. 39, 833-7.      
Chattopadhyay M, Goswami S, Rodes DB, Kodela R, Velazquez CA, Boring D, Crowell JA, and Kashfi K. (2010) Nitric oxide-releasing non-steroidal anti-inflammatory suppress NF-B signaling in vitro and in vivo through S-nitrosylation. Cancer Lett. 298, 204-11.      
Chattopadhyay M, Velazquez CV, Pruski A, Nia KV, Abdelatif K, Keefer LK, and Kashfi K. (2010) Comparison between NO-ASA and NONO-ASA as safe anti-inflammatory, analgesic, antipyretic, anti-oxidant, prodrugs. J Pharmacol Exp Ther. 335, 443-50.      
Nath N, Chattopadhyay M, Pospishil L, Cieciura LZ, Goswami S, Kodela R, Saavedra JE, Larry K. Keefer LK, and Kashfi K. (2010) JS-K, a nitric oxide-releasing prodrug, modulates -catenin/TCF signaling in leukemic Jurkat cells: Evidence of an S-nitrosylated mechanism. Biochem Pharmacol. 80, 1641-9.      
Nath N, Chattopadhyay M, Kodela R, Vlismas P, Boring D, Crowell JA, and Kashfi K. (2010) Modulation of stress genes expression profile by nitric oxide-releasing aspirin in Jurkat T leukemia cells. Biochem Pharmacol. 79, 1759-71.      
Kashfi K. (2009) Anti-Inflammatory Agents as Cancer Therapeutics. Adv in Pharmacol, 57, 31-89.      
Nath N, Vassell R, Chattopadhyay M, Kogan M, Kashfi K. (2009) Nitro-aspirin inhibits MCF-7 breast cancer cell growth: effects on COX-2 expression and Wnt/beta-catenin/TCF-4 signaling. Biochem Pharmacol. 78, 1298-304.      
Kashfi K, and Rigas B. (2007) The mechanism of action of nitric oxide-donating aspirin. Biochem. Biophys. Res. Comm. 358, 1096-1101.      
Gao J, Kashfi K, Liu X, and Rigas B. (2006) NO-donating aspirin induces phase II enzymes in vitro and in vivo. Carcinogenesis 27, 803-810.      
Ouyang N, Williams JL, Tsioulias G, Gao J, Latropoulos M, Kopelovich L, Kashfi K, and Rigas B. (2006) NO-donating aspirin prevents pancreatic cancer in a hamster tumor model. Cancer Res. 66, 4503-4511.      
Savle PS, Neptune NE, Yang Y, Rouden JH, Kite BL, Sugandhi EW, Macri RV, Kashfi K, and Gandour RD. (2005) Comparison of (+)- and (-)-Hemipalmitoylcarnitinium as Inhibitors of Hepatic Mitochondrial Carnitine Palmitoyltransferases in Diabetic Rats. Med. Chem. 5, 445-453.      
Spiegel A, Hundley TR, Chen J, Gao J, Ouyang N, Williams JL, Liu X, Go MF, Tsioulias G, Kashfi K, and Rigas B. (2005) NO-donating aspirin inhibits both the expression and catalytic activity of inducible nitric oxide synthease in HT-29 human colon cancer cells. Biochem. Pharmacol. 70, 993-1000.      
Kashfi K, and Rigas B. (2005) Is COX-2 a "collateral" target in cancer prevention? Biochem. Soc. Trans 33, part 4, 724-727.      
Kashfi K, and Rigas B. (2005) Molecular targets of nitric oxide-donating aspirin in cancer. Biochem. Soc. Trans 33, part 4, 701-704.      
Kashfi K, and Rigas B. (2005) Non-COX-2 targets and cancer: Expanding the molecular target repertoire of chemoprevention. Biochem. Pharmacol. (commentary) 70, 969-986.      
Rigas B, and Kashfi K. (2005) Cancer prevention: A new era beyond COX-2. J Pharmacol Exp Ther (Perspectives in Pharmacology, July cover issue) 314, 1-8.      
Gao J, Kashfi K, and Rigas B. (2005) In vitro metabolism of NO-donating aspirin: The effect of positional isomerism. J Pharmacol Exp Ther 312, 989-997.      
Kashfi K, Borgo S, Williams JL, Chen J, Glekas A, Traganos F, Benedini F, del Soldato P, Rigas B. (2005) Positional isomerism markedly affects the growth inhibition of colon cancer cells by NO-releasing aspirin: A structure-activity study in vitro and in vivo. J Pharmacol Exp Ther 312, 978-988.      
Nath N, Labaze G, Rigas B, and Kashfi K. (2004) NO-donating aspirin (NO-ASA) modulates ß-catenin expression in cultured human leukemia cells. Biochem. Biophys. Res. Comm 326, 93-99.      
Rigas B, and Kashfi K. (2004) Nitric oxide–donating NSAIDs as agents for cancer prevention. Trends in Mol. Med. 10, 324-330.      
Yeh RK, Chen J, Williams JL, Baluch M, Hundley TR, Rosenbaum RE, Kalala S, Traganos F, Benardini F, del Soldato P, Kashfi K, and Rigas B. (2004) NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: A general pharmacological property. Biochem. Pharmacol. 67, 2197-2205.      
Williams JL, Kashfi K, Ouyang N, del Soldato P, Kopelovich L, and Rigas B. (2004) NO-Donating Aspirin Inhibits Intestinal Carcinogenesis in MIN (APC Min/+) Mice. Biochem. Biophys. Res. Comm 313, 784-788.      
Nath N, Kashfi K, Chen J and Rigas B. (2003) NO-donating aspirin inhibits beta-catenin /TCF signaling in SW480 colon cancer cells more potently than aspirin by disrupting the nuclear beta-catenin–TCF association: Relevance to colon cancer chemoprevention. Proc. Natl. Aca. Sci., USA 100, 12584-12589.      
Williams J, Nath N, Chen J, Hundley T, Gao J, Kopelovich L, Kashfi K, and Rigas B. (2003) Growth Inhibition of Human Colon Cancer Cells by Nitric Oxide (NO)-Donating Aspirin is Associated with Cyclooxygenase-2 Induction and ß-Catenin/T-Cell Factor Signaling, Nuclear Factor-kB and NO Synthase 2 Inhibition: Implications for Chemoprevention. Cancer Res. 63, 7613-7618.      
Kashfi K, Ryann Y, Qiao LL, Williams JL, Chen J, Del Soldato P, Traganos F, and Rigas B. (2002) Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect. J Pharmacol Exp Ther (Cover Issue). 303, 1273-82.      
Kaza CS, Kashfi K, and Rigas B. (2002) Colon Cancer Prevention with NO-Releasing NSAIDs. Prost. &Other Lipid Mediat. 67, 107-120.      
Visvanathan K, Charles A, Bannan J, Pugach P, Kashfi K, and Zabriskie JB.(2001) Inhibition of Bacterial Superantigens by Peptides and Antibodies. Infection &Immunity 69, 875-884.      
Merritt GA, Aliprandis ET, Prada F, Rigas B, and Kashfi K. (2001) The Retinoid Fenretinide InhibitsProliferation and Downregulates Cyclooxygenase-2 Gene Expression in Human Colon Adenocarcinoma Cell Lines. Cancer Lett., 164, 15-23.      
Aliprandis ET, Merritt GA, Prada F, Rigas B, and Kashfi K. (1997) Fenretinide Inhibits Phorbol Ester-induced Cyclooxygenase-2 Expression in Human Colon Adenocarcinoma Cells. Biochem. Soc. Trans. 25, 457S.      
Bortuzzo C, Hanif R, Kashfi K, Staiano-Coico L, Shiff SJ, and Rigas B. (1996) The Effect of Leukotrienes B and Selected HETEs on the Proliferation of Colon Cancer Cells. Biochem. Biophys. Acta. 1300, 240-246.      
Kashfi K, McDougall CJ, and Dannenberg AJ. (1995) Comparative Effects of Omeprazole on Xenobiotic Metabolizing Enzymes in the Rat and Human. Clin. Pharma. Ther. 58, 625-630.      
Park EA, Mynatt RL, Cook GA, and Kashfi K. (1995) Insulin Regulates Enzyme Activity, Malonyl-CoA Sensitivity and mRNA Abundance of Hepatic Carnitine    Palmitoyltransferase-I. Biochem. J. 310, 853-858.      
Kashfi K, and Dannenberg AJ. (1995) Omeprazole Co-Induces Multiple Xenobiotic Metabolizing Enzymes in the Rat. Anna. New York Acad. Sci. 768, 237-242.      
Kashfi K, and Cook GA. (1995) Temperature Effects on Malonyl-CoA Inhibition of Carnitine Palmitoyltransferase-I. Biochim. Biophys. Acta. 1257, 133-139.      
Kashfi K, Cagen L, and Cook GA. (1995) Diabetes and Proteolysis: Effects on Carnitine Palmitoyltransferase-I and Malonyl-CoA Binding. Lipids 30, 383-388.      
Makar TK, Hungund BL, Cook GA, Kashfi K, and Cooper AJL. (1995) Lipid Metabolism and Membrane Composition are Altered in the Brains of Type II Diabetic Mice. J. Neurochem. 64, 2159-2168.      
Kashfi K, Yang EK, Roy Chowdhury J, Roy Chowdhury N, and Dannenberg AJ. (1994) Regulation of Uridine Diphosphate Glucuronosyltransferase Expression by Phenolic Antioxidants. Cancer Res. 54, 5856-5859.      
Kashfi K, Rimarachin JA, Weksler BB, and Dannenberg AJ. (1994) Differential Induction of Glutathione S-Transferases in the Rat Aorta Versus Liver. Biochem. Pharma. 47, 1903-1907.      
Cook GA, Mynatt RL, and Kashfi K. (1994) Yonetani-Theorell Analysis of Hepatic Carnitine Palmitoyltransferase-I Inhibition Indicates Two Distinct Inhibitory Binding Sites. J. Biol. Chem. 269, 8803-8807.      
Kashfi K, Mynatt RL, and Cook GA. (1994) Hepatic Carnitine Palmitoyltransferase-I Has Two Independent Inhibitory Binding Sites for Regulation of Fatty Acid Oxidation. Biochim. Biophys. Acta. 1212, 245-252.      
Kashfi K, and Cook GA. (1993) Inhibition of Carnitine Palmitoyltransferase of the Hepatic Mitochondrial Outer Membrane (CPT-I) by 2-Bromopalmitoyl-CoA. Biochem. Soc. Trans. 21, 503S.      
Kashfi K, and Cook GA. (1992) Proteinase Treatment of Intact Hepatic Mitochondria has Differential Effects on Inhibition of Carnitine Palmitoyltansferase by Different Inhibitors. Biochem. J. 282, 909-914.      
Kashfi K, and Cook GA. (1991) Malonyl-CoA Inhibits Proteolysis of Carnitine Palmitoyltransferase. Biochem. Biophys. Res. Comm. 178, 600-605.      
Kashfi K, Dory L, and Cook GA. (1991) Effects of Cholesterol Loading of Mouse Macrophages on Carnitine Palmitoyltransferase Activity and Sensitivity to Inhibition by Malonyl-CoA. Biochem. Biophys. Res. Comm. 177, 1121-1126.      
Kashfi K, Israel M, Sweatman TW, Seshadrei R, and Cook GA. (1990) Inhibition of Mitochondrial Carnitine Palmitoyltransferases by Adriamycin and Adriamycin Analogues. Biochem. Pharma. 40, 1441-1448.      
Cell Signaling and Molecular Targets in Cancer", (2011) Chatterjee M and Kashfi K Editors, Publisher, Springer USA.      
Book Chapters      
Kashfi K, and Cook GA. (1999) Topology of Hepatic Mitochondrial Carnitine Palmitoyltransferase-I. In "Current Views of Fatty Acid Oxidation and Ketogenesis: From Organelles to Point Mutations". Series: Advances in Experimental Medicine and Biology. Vol 466, pp27-42. P.A. Quant and S. Eaton, Eds., Kluwer Academic/Plenum Publishers.      
Neptune NE, Savle PS, Nam IU, Gandour RD, and Kashfi K. (2001) Comparative Effects of Hemipalmitoylcarnitinium (HPC) Stereoisomers on Hepatic Mitochondrial Carnitine Palmitoyltransferases (CPT) in the Diabetic Rat. In "New Avenues of Research in Fatty Acid Oxidation and Ketone Body Metabolism" pp5-9. P.A. Quant and S. Eaton, Eds.,FAOXK Press England.      

Kashfi K. (2009) Anti-Inflammatory Agents as Cancer Therapeutics. In: Contemporary Aspects of Biomedical Research: Drug Discover, Edited by SJ Enna and M Williams, Elsevier. Advances in Pharmacology, Volume 57, 2009, Pages 31-89.

<< Back To Directory